Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer
jRCT2080225360Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of H3B-6545 in breast cancer (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-limiting toxicities (DLTs) and Treatment-emergent adverse events (TEAEs). Started Aug 2020; status: completed.
02
Drugs
H3B-6545
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080225360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225360.